The UK's health regulator has approved Moderna's COVID-19 vaccine for use in children aged 12 to 17 years, it said on Tuesday, weeks after Pfizer's shot was given the green light for deployment ahead of schools reopening.
The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed the vaccine, known as Spikevax, is safe and effective in this age group, it said.
While most children develop mild or no symptoms with COVID-19, they are still able to spread the virus and some remain at risk of becoming seriously ill.
Moderna's vaccine was recommended for use in adolescents by European regulators
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)